Table 3.
Summary of phase III trial (first- and second-line) in advanced hepatocellular carcinoma
| Treatment | Principal targets | Patients (n) | Median overall survival |
|---|---|---|---|
| First-line | |||
| Sunitinib vs SOR | VEGFR, PDGFRa/b, c-KIT, FLT3, RET | 1074 | 8.1 vs 10 months |
| Cheng et al. 2013 | HR 1.31 (1.13-1.52), p = 0.0019) | ||
| Brivanib vs SOR (BRISK-FL) | VEGFR, FGFR | 1155 | 9.5 vs 9.9 months |
| Johnson et al. 2013 | HR 1.07 (0.94-1.23), p = 0.3116 | ||
| Linifanib vs SOR | VEGFR, PDGFR | 1035 | 9.1 vs 9.8 months |
| Cainap et al. 2012 | HR 1.046 (0.896-1.221), p = 0.1785 | ||
| Erlotinib/SOR vs placebo/SOR (SEARCH) | EGFR | 720 | 9.5 vs 8.5 months |
| Zhu et al. 2012 | HR 0.929 (0.781-1.106), p = 0.204 | ||
| Second-line | |||
| Brivanib vs BSC (BRISK-APS) | VEGFR, FGFR | 395 | 9.4 vs 8.2 months |
| Llovet et al. 2013 | HR 0.89 (0.69-1.15), p = 0.3307 | ||
| Everolimus vs BSC (EVOLVE-1) | mTOR | 546 | 7.6 vs 7.3 months |
| Zhu et al. 2014 | HR 1.05 (0.86-1.27), p = 0.675 | ||
BSC = best supportive care, HR = hazard ratio, SOR = sorafenib.